How incretin therapy changes diabetes and prediabetes management - PACE-CME

How incretin therapy changes diabetes and prediabetes management

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Broadcast Replay
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
- Riccardo Maria Inciardi, MD, PhD
- Cristina Gavina, MD, PhD
- Giuseppe Galati, MD
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC.25
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
- Darren K. McGuire, MD
Expert opinion on the SOUL study results
Expert opinion on the SOUL study results
ACC.25
Expert opinion on the SOUL study results
- Gina Lundberg, MD
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC.25
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
- Marc Bonaca, MD